Renaissance Capital logo

Greenwich LifeSciences Priced, Nasdaq: GLSI

Phase 3 biotech developing immunotherapies for breast cancer.

Industry: Health Care

First Day Return: -13.0%

Industry: Health Care

We are a biopharmaceutical company developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. We are planning to commence a Phase III clinical trial in 2020.
more less

Greenwich LifeSciences (GLSI) Performance